---
document_datetime: 2025-11-14 10:19:32
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/triumeq-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: triumeq-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 15.2107677
conversion_datetime: 2025-12-26 10:27:31.718161
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Triumeq

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                        |
|----------------------|-----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------|
| Variation type II /  | This was an application for a variation | 16/10/2025                          |                                             | SmPC and PL                      | Section 4.8 of the SmPC was updated to reflect |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000249653                     | following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section 4.8 of the SmPC in order to add 'sideroblastic anaemia' to the list of adverse drug reactions (ADRs) with frequency 'very rare', based on post- marketing data. The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to include information about placental transfer for Triumeq and Dovato following the outcome of procedure EMEA/H/C/WS2620, to introduce minor editorial and formatting changes to the PI, and to update the list of   |            |     | 'sideroblastic anemia' with frequency 'unknown' of dolutegravir (Tivicay) and its combinations (Triumeq, Juluca, Dovato). Additionally, a footnote was added to table 4.8, informing about cases of sideroblastic anemia with dolutegravir containing regimens. For more information, please refer to the Summary of Product Characteristics.   |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IA / EMA/VR/0000295242 | A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 18/09/2025 | N/A |                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|                                       | substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted   |            |     |                                                                                                                                                                                                                                                                                                                               |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000278110 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Change in due date for category 1, 2 or 3 studies in the RMP and/or Annex II - Accepted                                                                                                                                                                                                                                                                                                                                                                   | 04/09/2025 | N/A | To update the RMP with the latest available post- authorisation exposure data and to include the 2024 Antiretroviral Pregnancy Registry data. To update the submission date for the final CSR for category 3 PASS study DOLOMITE-NEAT ID (208759)from 30 September 2025 to 30 September 2026 for Tivicay, Triumeq and Juluca. |

<div style=\"page-break-after: always\"></div>

|                                       | post-authorisation exposure data and to include the 2024 Antiretroviral Pregnancy Registry data. To update the submission date for the final CSR for category 3 PASS study DOLOMITE-NEAT ID (208759)from 30 September 2025 to 30 September 2026 for Tivicay, Triumeq and Juluca.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |     |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IA / EMA/VR/0000244755 | A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted B.III.1.a European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - B.III.1.a.2 Updated certificate from an already approved manufacturer - Accepted A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical | 22/01/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                            | Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where   |
|----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUR / EMA/PSUR/0000269008 | - -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>